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Background: Now with the new triple therapie options sus-
tained viral response rates increased very much in genotype 1
patients. This therapie is very suitable for Turkey because of dom-
inance of genotype1 inTurkey (∼95%).
Methods & Materials: HCV RNA isolated with magnetic par-
ticle technique and detected with Bosphore HCV Kit v2 on the
real-time PCR platform (Anatolia Biotechnology, Istanbul, Turkey).
HCV NS3 region (30 - 181 aa) has been analysed for telaprevir and
boceprevir resistance mutation after population based sequencing.
NS3 inhibitors resistance mutation determination by geno2pheno
drug resistance tool (coreceptor.bioinf.mpi-inf.mpg.de). The fold
change of NS3 inhibitors resistance mutation is based on the IC50
valuesof thedrugs for thedifferentmutations and thewild typeand
fold change cutoff was 1.2. Consensus sequence from strain HPC-
PLYPRE, HPCCGAA, HPCJCG, HPCHUMR, HPCCGS and AY051292 for
HCV genotype 1b and H77 for type 1a sequences has been used in
the resistance mutation analysis.
Results: We analysed 36 patients. HCV RNA from 6 different
proviencesof Turkey before beginning telaprevir treatment and
found in3 (8,3%)patient telaprevir resistance and in1 (2,8%)patient
boseprevir resistance.
Only telaprevir is now available in Turkey. All this 36 patients
are relapsed after ﬁrst pegylated interferon and ribavirin treatment
or treatment naive cirrhotic patients.
Table 1;Demographic features and results ofHCVNS3 inhibitors
resistance mutation analysis in the telaprevir started treatment
naive Turkish patients with chronic hepatitis C.
Characteristics Study group
Gender, M/F, n(%) 12 (33%)/24 (66%)
Age, median (range) 56.6 (25 - 76)
HCV RNA load, median (range), IU/ml 4.2 +E7 (33+E2 - 10+E9)
HCV genotype, n(%) 1b; 35 (97.2)
1a; 1 (2.8)
ALT, median (range), U/L 67 (16 - 202)
AST, median (range), U/L 49.7 (8 - 116)
NS3 inhibitors resistance, n(%) Telaprevir; 3 (8.3)
Boceprevir; 1 (2.8)
NS3 inhibitors resistance mutation Telaprevir
T54S
L155I
I132V
Boceprevir
R109K
NS3 inhibitors resistance mutation T54S; 1.9
fold change (fold change cutoff: 1.2) L155I; 4.3 - 16.4
I132V; 1.8
R109K; 1.2
Conclusion: Despite this resistance proﬁle all the patients HCV
RNA at the ﬁrst month of therapy were under 1000 IU/mL. We
will see clinical aspects of this resistance pattern at the end of the
therapy.
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Background: Rotavirus (RV) is the most common cause of
severe diarrhoeal illness in infants and young children 0-5 years of
age in both developing and developed countries. However, limited
data exist on rotavirus (RV) infection in Kano, North-Western
Nigeria. This Study was aimed at determining the prevalence
and genotyping of rotavirus among these children using Enzyme
Linked ImmunoSorbent Assay (ELISA) and Reverse Transcription-
Polymerase Chain Reaction (RT-PCR).
Methods & Materials: A total of 285 stool samples were col-
lected from infants and children 0-5 years of age, who reported
with diarrhea in six different hospitals in Kano, Nigeria between
November 2009 and July 2010. The diarrhoeic Stools were ana-
lyzed for RV antigen (ELISA), and theRVpositive stoolswere further
subjected to VP7 and VP4 genotyping using gene speciﬁc primers
(RT-PCR).
Results: Rotavirus was detected in 36.5% (104/285) of the diar-
rhoeic children. The infectionoccurred throughout the studyperiod
withhigherpeaks in thedriermonthofApril 77.6% (38/49) and low-
est in July 12.2% (5/41) (Pearson Chi Square analysis: X2= 27.720,
P <0.05, df = 1). The highest prevalence of RV infection was in chil-
dren 41-50 months 50% (3/6) The RV was detected more in male
37.2% (61/164) than female 35.4% (43/121) children and no statisti-
cally signiﬁcant difference was observed (P >0.05). Three different
rotavirus P-genotypes (P[8], P[4], and P[6]) were detected in this
study and P[6] (48.5%) was the most commonly detected. Mixed
infection were detected and consisted only of P[8] + P[6]. Six differ-
ent G-genotypes were detected. The predominant genotype was
G2 35.0% (36/103). The most common G and P combination was
